Answers are grounded in this paper and cite their sources.
Breast cancer progression is closely linked to immune cells within the tumor microenvironment (TME), but the immune landscape differences across HER2-positive (HER2+), triple-negative (TNBC), and ER-positive (ER+) subtypes have yet to be systematically characterized. In this study, we characterized immune landscape differences across HER2-positive (HER2+), triple-negative (TNBC), and ER-positive (ER+) breast cancers using single-cell RNA sequencing data, focusing on T cells, macrophages, and B cells. Our analysis revealed that cytotoxic CD8 + T cells were more abundant in TNBC but showed signs of dysfunction. Macrophage subsets, including an NDUFB8 + population, exhibited divergent functional orientations across subtypes. B cells in TNBC exhibited functional alterations, characterized by a decreased proportion of plasmablasts and an increased proportion of memory B cells. Single-cell regulatory network inference and clustering (SCENIC) analysis predicted a set of subtype-specific candidate transcription factors (TFs), including E2F8 across all subtypes and ATF7 in HER2 + tumors, whose activity correlated with clinical outcomes. Finally, mapping multicellular communication networks revealed both conserved and subtype-specific signaling pathways. Together, these results present a detailed transcriptional landscape of immune heterogeneity in breast cancer and contribute novel insights that may inform the design of subtype-specific immunotherapies.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: